CHAMPIONS ONCOLOGY, INC. (CSBR) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, CHAMPIONS ONCOLOGY, INC.'s filing signal turned negative.

Champions Oncology, Inc. is a technology-enabled research organization focused on creating solutions for drug discovery and development, leveraging a proprietary bank of approximately 1,500 Patient Derived Xenograft (PDX) models. These models are integrated into advanced in vivo and ex vivo pharmacology platforms to provide deep insights into therapeutic programs, forming the core of their "Datacenter" which combines proprietary and public datasets. The company offers a suite of services including research services for biopharmaceutical companies, sales of PDX model data and oncology research SaaS tools, and the discovery and development of novel oncology therapeutics. Revenue from research services, which has grown at an average annual rate of 12% since 2019, represents the primary revenue stream, with total revenues reaching approximately $56.9 million in fiscal year 2025.

Primary revenue is driven by research services provided to pharmaceutical and biotechnology companies, supplemented by data licensing and Software as a Service (SaaS) offerings.